Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Florida's Medicaid Fraud Control Unit secured the win through a multistate action. "Actions, like those alleged here, must be ...

Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...

Pfizer Inc. (PFE) is my Top Pick for income-oriented investors in 2025. The past year was unkind to the pharmaceutical giant because it does not have diabetes or weight loss drugs in its portfolio.

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 8 includes Lara Exploration, Imperial Oil, Avino ...

Other recent buys include Biohaven for US$11.6bil and Arena Pharmaceuticals for US$6.7bil. In May, Pfizer embarked on a cost-cutting plan meant to save US$1.5bil by the end of 2027. Still ...

Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that Biohaven knowingly submitted or caused false claims to be submitted to Medicaid and other federal health care ...